One year on: The US Inflation Reduction Act

15-08-2023

Alice Valder Curran and Cullen Taylor

One year on: The US Inflation Reduction Act

d.ee_angelo / Shutterstock.com

This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.

The US Inflation Reduction Act (IRA) came into force on August 16 2022.

Over the past 12 months, most life sciences manufacturers with products expected to be reimbursed by the US Medicare system have now internalised, at least to some extent, the impact that the act will have on their research and development and commercial launch strategies.

What the industry may not yet have grasped is the impact it is likely to have on their IP partnering, collaboration, and patent litigation strategies. The new IRA framework raises a number of considerations for IP practitioners supporting life sciences companies of any size.


Hogan Lovells, US inflation reduction act, Medicare, QSSD, IP practitioners, QSSD, NDA, Biologics License Application

LSIPR